About spyglass pharma inc - SGP
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
SGP At a Glance
SpyGlass Pharma, Inc.
27061 Aliso Creek Road
Aliso Viejo, California 92656
| Phone | 1-949-284-6904 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -39,869,000.00 | |
| Sector | Health Technology | Employees | 65 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
SGP Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
SGP Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -613,369.231 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
SGP Liquidity
| Current Ratio | 12.671 |
| Quick Ratio | 12.671 |
| Cash Ratio | 12.516 |
SGP Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -56.732 |
| Return on Equity | -67.706 |
| Return on Total Capital | -37.163 |
| Return on Invested Capital | -64.929 |
SGP Capital Structure
| Total Debt to Total Equity | 1.497 |
| Total Debt to Total Capital | 1.475 |
| Total Debt to Total Assets | 1.36 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 1.475 |